The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
Abstract
BACKGROUND: A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection. METHODS: A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2 : 1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months. RESULTS: A total of 5403 volunteers (5095 men and 308 women) were evaluated. The vaccine did not prevent HIV-1 acquisition: infection rates were 6.7% in 3598 vaccinees and 7.0% in 1805 placebo recipients; vaccine efficacy (VE) was estimated as 6% (95% confidence interval, -17% to 24%). There were no significant differences in viral loads, rates of antiretroviral-therapy initiation, or the genetic characteristics of the infecting HIV-1 strains between treatment arms. Exploratory subgroup analyses showed nonsignificant trends toward efficacy in preventing infection in the highest risk (VE, 43%; n=247) and nonwhite (VE, 47%; n=914) volunteers (P=.10, adjusted for multiple subgroup comparisons). CONCLUSIONS: There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
Survival analysis using the SAS system : a practical guide
Allison, P. D. (1995) · Medical Entomology and Zoology · Cited by 2,402
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Applying Cox Regression to Competing Risks
Lunn, M., & McNeil, D. (1995) · Biometrics · doi:10.2307/2532940 · Cited by 975
A Gender Gap in Autoimmunity: Task Force on Gender, Multiple Sclerosis and Autoimmunity
Whitacre, C. C., Reingold, S. C., O'Looney, P. A., Blankenhorn, E., Brinley, F., Collier, E., Duquette, P., Fox, H., Giesser, B., Gilmore, W., et al. (1999) · Science · doi:10.1126/science.283.5406.1277 · Cited by 851
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Wald, A., & Link, K. (2002) · The Journal of Infectious Diseases · doi:10.1086/338231 · Cited by 691
Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., & Eichberg, J. W. (1990) · Nature · doi:10.1038/345622a0 · Cited by 590
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
Fowke, K. R., Nagelkerke, N. J., Kimani, J., Simonsen, J. N., Anzala, A. O., Bwayo, J. J., MacDonald, K. S., Ngugi, E. N., & Plummer, F. A. (1996) · The Lancet · doi:10.1016/s0140-6736(95)12269-2 · Cited by 463
Cited by
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Sanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
The Challenge of HIV-1 Subtype Diversity
Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., & Hammer, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706737 · Cited by 635
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
GP120: Target for Neutralizing HIV-1 Antibodies
Pantophlet, R., & Burton, D. R. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090557 · Cited by 445
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
Delany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
The Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Challenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Triggering TLR signaling in vaccination
van Duin, D., Medzhitov, R., & Shaw, A. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364
Buonaguro, L., Tornesello, M. L., & Buonaguro, F. M. (2007) · Journal of Virology · doi:10.1128/jvi.00872-07 · Cited by 359
Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428405 · Cited by 355
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Do Kwon, Y., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., Joyce, M. G., Guttman, M., Ma, X., Narpala, S., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3051 · Cited by 345
Walker, B. D., & Burton, D. R. (2008) · Science · doi:10.1126/science.1152622 · Cited by 338
Barouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 336
Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Reed Clark, K. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310
Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K. L., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K., & Lange, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34706 · Cited by 304
Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis367 · Cited by 284
Smith, D. K., Pals, S. L., Herbst, J. H., Shinde, S., & Carey, J. W. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318256b2f6 · Cited by 278
A 2020 vision for vaccines against HIV, tuberculosis and malaria
Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
McElrath, M. J., & Haynes, B. F. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.011 · Cited by 270
Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, M., Beileke, S., Schäfer, S., Zhong, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade2798 · Cited by 264
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward
Padian, N. S., Buvé, A., Balkus, J., Serwadda, D., & Cates, W. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60885-5 · Cited by 264
Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., Seage III, G. R., Sloan, C. E., Sax, P. E., & Walensky, R. P. (2009) · Clinical Infectious Diseases · doi:10.1086/597095 · Cited by 259
An HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257
Smith, D. K., Herbst, J. H., Zhang, X., & Rose, C. E. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000461 · Cited by 236
Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C., Casapia, M., Santiago, S., Gilbert, P., Corey, L., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis342 · Cited by 210
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities.
Ackers, M.-L., Greenberg, A. E., Lin, C. Y., Bartholow, B. N., Goodman, A. H., Longhi, M., & Gurwith, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034972 · Cited by 55
An Assessment of the Role of Chimpanzees in AIDS Vaccine Research
Bailey, J. (2008) · Alternatives to Laboratory Animals · doi:10.1177/026119290803600403 · Cited by 49
Per-partner condom effectiveness against HIV for men who have sex with men.
Johnson, W. D., O’Leary, A., & Flores, S. A. (2018) · AIDS · doi:10.1097/qad.0000000000001832 · Cited by 44
Tonks, A. (2007) · BMJ · doi:10.1136/bmj.39240.416968.ad · Cited by 23
Dennison, S. M., Anasti, K. M., Jaeger, F. H., Stewart, S. M., Pollara, J., Liu, P., Kunz, E. L., Zhang, R., Vandergrift, N., Permar, S., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01031-14 · Cited by 18
Metadata
- Authors
- The rgp120 HIV Vaccine Study Group
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03
- Volume
- 191
- Issue
- 5
- Pages
- 654-665
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2240372320
- Cited by
- 952
- References
- 31
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.